

Economics Legislation Committee
ANSWERS TO QUESTIONS ON NOTICE
Industry, Innovation and Science Portfolio
2016-17 Supplementary Budget Estimates
20 October 2016

AGENCY: AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION

TOPIC: Sales of radioisotopes

REFERENCE: Written Question – Senator Carr

QUESTION No.: SI-80

1. In the 2014/15 financial year ANSTO reported sales of \$44.3 million in radioisotopes. Is that correct? What is the amount for 2015/16?
2. How much of those sales was in the domestic market and how much was exported?
 - a. What is ANSTO's market position as a provider of medical radioisotopes? What is your market share domestically and globally?

ANSWER

1. The figure of \$44.3 million for radioisotope sales for the 2014/15 financial year is correct. In 2015/16, the figure was \$48.3 million.
2. As a commercial operation, ANSTO does not publicly disclose details of its nuclear medicine exports.
 - a. ANSTO's domestic market position for technetium 99m (Tc-99m) is 100 per cent, and 80 per cent for all other medical isotopes. Exports primarily consist of molybdenum-99 (Mo-99), with ANSTO currently accounting for around 9 per cent of global supply.